Background. The CYP4503A5*1 genotype is associated with lower tacrolimus concentrations. Although its effect is important, it incompletely explains the variability in tacrolimus concentrations and has a relatively low minor allele frequency in whites relative to African Americans (AA). Methods. We studied clinical and recipient genetic correlates of dose-normalized tacrolimus troughs (nϭ12,277) in the first 6 months posttransplant using a customized single-nucleotide polymorphism chip with 2722 variants in a large, ethnically diverse (144 AA and 551 non-AA) adult kidney transplant population through a seven-center consortium.
due to the unclear impact on clinical outcome, conflicting findings, and modest variant effects.
Tacrolimus is the most commonly used calcineurin inhibitor (7) . It is metabolized by CYP3A in the gut and liver, and transported in the gut by P-glycoprotein (P-gp), an efflux pump, which is encoded by the multidrug-resistant protein (MDR1)/ABCB1 gene (8 -12) . Tacrolimus has a narrow therapeutic index necessitating therapeutic monitoring of blood concentrations (13) (14) (15) . There is high interpatient variability in tacrolimus concentrations and the dose required to achieve the therapeutic range; therefore, there is intensive interest in using genetics to optimize dosing.
The influence of variants on tacrolimus metabolism has been extensively studied and recently reviewed (16, 17) . One or more CYP3A5*1 alleles (rs776746) results in higher clearance, lower concentrations, higher dose requirements and delayed time to therapeutic concentrations (18 -30) . Despite the clear differences between the CYP3A5*1 and *3 genotypes, they explain up to 45% of the variability in dose (31) and 30% of clearance variability (32) , suggesting additional determinants of drug disposition. CYP3A4 variants have been studied with conflicting results (18, 21, 23, 24) . Most studies have shown that the MDR1 variants have small or no effects on tacrolimus pharmacokinetics. (18, 21, 23-25, 29, 31, 33-36) . To date, these variants do not explain enough variation in metabolism thereby limiting the enthusiasm for clinical use. To directly address these issues, we conducted an evaluation of 2722 genetic variants towards tacrolimus pharmacokinetics in 695 kidney transplant recipients. Identification of the important variants will allow for the development of dosing equations to individualize therapy.
RESULTS

Transplant Recipients and Tacrolimus Trough Measurements
Recipient characteristics are shown in Table 1 . A total of 12,277 tacrolimus trough concentrations were studied (Table 1) in seven centers in an ethnically diverse population. Tacrolimus oral doses and troughs varied between centers. The median (interquartile range) daily dose (mg) over the 6-month study period in centers 1 to 7 were 8 (5-11), 5 (4 -6), 4 (3-6), 6 (4 -8), 6 (4 -8), 6 (4 -8) , and 6 (4 -8), respectively. The trough concentrations (ng/mL) in centers 1 to 7 were 9.5 (8.0 -11.4), 10.5 (7.4 -13.0), 7.9 (6.1-10.1), 9.7 (7.5-12.2), 8.9 (7.1-10.6), 9.1 (7.0 -11.3), and 6.6 (4.7-8.7), respectively. Troughs increased over the first 2 weeks and then stabilized (Fig. 1) . The first trough concentration, measured within 4 days after transplantation, was less than 5 ng/mL in most subjects. Figure 1 shows the differences in troughs between African Americans (AA) and non-AAs in the first 6 months posttransplant. The first trough in the AA group was a median (interquartile range) of 2.1 (1.2-3.5) ng/mL with a daily tacrolimus dose of 4.0 (4.0 -5.0) mg/day. In contrast, the non-AA group achieved a higher first trough (5.0 [3.1-8.2] ng/mL), despite a similar daily dose (4.0 [4.0 -6.0] mg/day). Although the first trough was low in both groups, more AAs had troughs less than 8 ng/mL (96.6%) than non-AA (73.9%; PϽ0.0001). Over the 6-month study period, AAs received a 60% higher median daily dose (PϽ0.0001) but yet achieved median troughs that were 2.1 ng/mL lower (PϽ0.0001) than non-AA recipients (Table 1) .
Clinical Factors Associated With Tacrolimus Trough Concentrations
Clinical factors (AA vs. non-AA, enrolling center, recipient gender, age, donor type, diabetes at transplant, time of trough posttransplant, calcium channel blocker [CCB], angiotensin-converting enzyme [ACE] inhibitor and corticosteroid use at time of trough, creatinine clearance [CrCl] nearest the trough and acute rejection Ϯ14 days of trough) were explored for their association with log-transformed dose-normalized tacrolimus trough concentrations. Race (PϽ0.0001), center (PϽ0.0001), gender (PϽ0.0001), age (PϽ0.0001), diabetes (Pϭ0.003), CCB (Pϭ0.04) use, and time of trough measurement (PϽ0.0001) were associated with troughs and ACE inhibitor use neared significance (Pϭ0.07). AA race and the first three troughs measurements were each associated with lower trough concentrations whereas male gender, diabetes, and CCB use were associated with higher troughs. AA race was associated with a reduction in log-transformed dose-normalized trough of 0.04 relative to non-AAs. Male gender, diabetes, and CCB use each were associated with an increase in log-transformed dosenormalized troughs of 0.17, 0.12, and 0.03, respectively. The effect of age was quadratic, with higher troughs between 45 and 75 years with a maximum at 60 years. 
Single Variant Analysis for Association With Tacrolimus Trough Concentrations
The CYP3A5 variant (rs776746, Aϭ*1, Gϭ*3) was the most important variant associated with troughs after adjustment for clinical factors. Dose requirements were higher and troughs lower in individuals with one or two A alleles. The presence of one A allele was associated with a 36% reduction in log-transformed dose-normalized troughs (Ϫ0.44Ϯ0.03 [SE] ) and a 59% reduction if two A alleles were present (Pϭ2.4ϫ10 Ϫ33 , Fig. 2 ). Median (interquartile range) tacrolimus daily doses and troughs for the three genotype groups were as follows: 8 (6 -10) mg and 5.8 (4.1-7.9) ng/mL for *1/*1, 7 (5-10) mg and 7.1 (5.1-9.3) ng/mL for *1/*3, and 4.5 (3-6) mg and 8.4 (6.5-10.5) ng/mL for the *3/*3 genotype. Dose-normalized troughs (ng/mL per mg/kg) were 54.3 (37.9 -80.3), 77.8 (53.1-114.6), and 141.1 (91.7-214.5) in those with CYP3A5*1/*1, *1/*3 and *3/*3 genotypes, respectively. The CYP3A5*1 allele was more frequent in AA (minor allele frequency [MAF]ϭ0.65) than non-AA recipients (MAFϭ0.08). Fifty variants, besides CYP3A5*1, were significant towards dose-normalized troughs after controlling for the false discovery rate (FDR) at 20% and were primarily variants in CYP3A5, CYP3A7, CYP3A4, and CYP3A43 genes (variants not shown). These variants are in the same chromosomal region with linkage disequilibrium with rs776746; therefore, all further analyses were adjusted for rs776746.
The top variants, after adjustment for rs776746 and the significant clinical factors, towards troughs are shown in Table A , Supplemental Digital Content 4, http://links.lww.com/TP/A325. No variants met significance after controlling the FDR at 20% although 39 variants achieved a P value less than 0.01. The most frequently represented variants were from the CYP, COMT, MSH, ATF, XRCC5, and FMO genes. Variants within the CYP3A gene, CYP3A4 (rs7801671, rs12114000, and rs2687117), CYP3A7 (rs2687080 and rs776740) and CYP3A5 (rs10264272) were associated with 0.18 to 0.28 increase in log-transformed dose-normalized troughs (20%-32% increase in dose-normalized trough). The CYP3A variants had higher MAF in the AA population (9%-32%) than the non-AA (Յ0.2%) and large effects on trough concentrations (0.18 -0.28 for one allele). We previously described no association between variants and acute rejection, graft survival, and survival (37) .
Multiple Variant Analysis for Association With Initial Tacrolimus Trough Concentrations
Multiple regression models for the first trough in week 1 were developed using the important clinical factors, CYP3A5 (rs776746) and the 39 variants from Table A (Supplemental Digital Content 4, http://links.lww.com/TP/A325). Final models were developed separately for all subjects, for non-AA and for AA ( Table 2 ). The models explained 45.71% to 52.54% of total variability. Center was important, explaining 19.19% to 37.27% of variation. CYP3A5 was significant, accounting for 2% to 6% of variation. Six additional variants were significant in each of the AA and non-AA groups each explaining 2% to 6% of variation. CYP3A5 and COMT (rs2239393) variants overlapped between the groups. In AAs, three variants (genes CYP3A4, CNAP1, and FASTK) had large effect sizes (Ն0.38). Diabetes was an important factor explaining approximately 2% of the variation. These factors were confirmed by bootstrapping and support their association with trough concentrations (see Appendix 1, Supplemental Digital Content 1, http://links.lww.com/TP/A322) although the AA model was relatively less stable compared with the full data.
DISCUSSION
Tacrolimus is metabolized by CYP3A enzymes to form active and inactive metabolites (11, 38 -40) . In vitro, the CYP3A5 enzyme has twice the intrinsic tacrolimus clearance of CYP3A4 (41) . In hepatic enzymes from CYP3A5*1 allele carriers, 60% is metabolized through CYP3A5. Transplant (18, 20, (22) (23) (25) (26) (27) (28) (29) (30) (31) (32) . We confirmed CYP3A5*1 is an important variant and is associated with a reduction in troughs and explained only 2% to 6% of total variation in troughs. Other variants (including CYP3A4) explained equal or more of total variation (Table 2 ). This is consistent with previous data where variants each accounted for 3% to 9% of variability in tacrolimus clearance (32) . Variants in the COMT and CYP3A4 genes were important in our analysis. Catechol-O-methyltransferase (COMT) enzymes are responsible for O-methylation of dopamine, epinephrine, and norepinephrine; and involvement in tacrolimus metabolism has not been described whereas variants in the CYP3A4 are relevant, particularly in AAs (42 (28, 29, 31) . The variants were different in the AA and non-AAs (Table 2) and were only identifiable when the races were analyzed separately. Several variants identified in the AAs had large effect sizes and may in part explain the differences in troughs between races. Warfarin pharmacogenetic studies have shown that clinical factors, effect sizes, and pertinent genotypes differ by race (44, 45) . We found that early troughs were low in both groups. The non-AA group quickly achieved troughs more than 8 ng/mL whereas the AAs median trough remained less than 8 ng/mL (Fig. 1) , despite 60% higher doses. Lower troughs and requirement for higher doses in AAs have been described (38, 46 -48) . The low troughs may be due to high clearance due to CYP3A5*1 and other variants and inadequate starting dose; although, this does not sufficiently explain the persistently low troughs in AAs over the first 6 months. It is possible that the high degree of genetic diversity in the CYP3A or other genes, and the large effect size may result in longer periods of trial and error dosing. In a recent study, the intersubject pharmacokinetic variability in tacrolimus area under the curve was 41.1% higher in patients with CYP3A5*3/*3 compared with *1/*1 or *1/*3, suggesting that patients with variants are more difficult to manage (49) .
Center was an important factor toward troughs explaining 19% to 37% of the total variability. The effect of center is confounded by genotype (more AAs carry CYP3A5*1) and race (AAs were mostly from one center). Center effects are also possible given the heterogeneity in concomitant medications, timing of troughs, environment, and diet. We found that diabetes at time of transplant was important towards troughs with an effect as large as some variants. However, in a small study of 11 diabetics and 9 nondiabetics the rate of tacrolimus absorption was slowed in diabetics but the extent of absorption and troughs were unchanged (50) . Other factors influence tacrolimus pharmacokinetics including route of administration, hematocrit and hepatic function and should be evaluated in future studies (8, 32, 51, 52) .
Drug interactions pose a dilemma in pharmacogenetic studies (53) (54) (55) (56) (57) (58) (59) . We found that the concomitant administration of CCBs, ACE inhibitors, and corticosteroids were not significant towards troughs in the final models. Only class of concomitant medication was collected in our study. CCBs are not equipotent in their inhibitory activity towards tacrolimus and it is possible that the effect of CCBs with potent CYP3A inhibitory effects, such as diltiazem, is underestimated. The interaction between corticosteroids and tacrolimus is controversial (53, 56, 58, 60, 61) . It is possible that high doses of corticosteroids may induce metabolism (53). We did not collect corticosteroid dosing information and are unable test this possibility. We have no information on concomitant administration of antifungals, which may be pertinent (62, 63) .
To our knowledge, this is first pharmacogenetic study to explore a broad panel of variants (nϭ2722) and the largest group of AAs studied toward tacrolimus troughs. We confirmed that CYP3A5 is important and identified additional variants with effects as large or larger than CYP3A5. Trough concentrations are lower in AAs compared with non-AA subjects and therefore require higher tacrolimus doses. Variants important towards troughs differed between the AA and non-AA subjects. This study provides the data necessary to now develop dosing equations that use genotype and relevant clinical variables instead of weight to determine initial doses. These variants can now be validated in independent groups.
MATERIALS AND METHODS
Study Design
This is a seven-center, prospective, observational study in 695 subjects to identify novel variants associated with tacrolimus troughs using a customized SNP chip. Transplant recipients were recruited from the first 1000 subjects of the prospective arm of the Long-term Deterioration of Kidney Allograft Function (DeKAF) study, which is designed to characterize the causes of late allograft failure (64 -66) . The study is registered at www. clinicaltrials.gov (NCT00270712). Transplant recipients were eligible if they were undergoing kidney or simultaneous kidney-pancreas transplantation, 18 years and older and to receive tacrolimus. Subjects were enrolled at time of transplant and signed informed consents approved by the Institutional Review Boards.
Tacrolimus trough concentrations, measured before an oral dose, were obtained as part of clinical care for the first 6 months posttransplant. Two measurements, if available, were obtained in each of weeks 1 to 8 and in each of months 3, 4, 5, and 6 for a maximum of 24 measurements per patient. Tacrolimus doses were adjusted to achieve individual institutional trough targets but in general were 8 to 12 ng/mL in months 0 to 3 and 6 to 10 ng/mL in months 4 to 6. Troughs were normalized for dose by taking the ratio of the trough concentration (ng/mL) by the total daily tacrolimus dose (mg/kg). Dose in mg/kg was used since this is the common clinical method for dose determination. Tacrolimus concentrations (nϭ12,277) were measured from whole blood by each institutions preferred analytical technique. Liquid chromatography-mass spectroscopy was used to measure 97.1% concentrations.
All participants received a tacrolimus-based immunosuppressive regimen with mycophenolate, steroids, with and without antibody induction per transplant center preference. Donor and recipient characteristics, race, serum creatinine (SCr), and estimated CrCl (67) , concomitant medications at time of each trough, acute rejection as diagnosed by the treating physician were obtained from the medical record.
Genotyping
Pretransplant recipient DNA was isolated from lymphocytes obtained from blood after RBC lysis. Genotyping was done using a customized Affymetrix GeneChip (Affymetrix, Santa Clara, CA) (68, 69) . Additional variants were genotyped using SNPlex (Applied Biosystems, Foster City, CA) and Sequenom (Sequenom, San Diego, CA). The variants were within genes in pathways associated with immunity, cell cycle, signaling, growth, proliferation, differentiation, movement, structure and death, inflammation, hematologic systems, and approximately 700 variants related to drug absorption, disposition, metabolism, and excretion. Validated, functional polymorphisms including nonsynonymous variants with a MAF more than 5%, and variants within conserved (in humans and mouse) transcriptional regulatory regions were chosen. In the absence of functional variants, intragenic tagging variants were used. Genotyping is described in (see Appendix 3, Supplemental Digital Content 3, http://links.lww.com/TP/A324).
Data quality was assessed by negative controls and duplicate samples (3% on Affymetrix, 7% SNPlex, and 1% Sequenom). On Affymetrix, duplicate samples from 31 individuals were genotyped with more than 99% concordance. Variants with concordance less than 90% and calls less than 60% were excluded. Twenty variants were run on multiple platforms and had a concordance rate of more than 97% and with calls more than 82%. The HardyWeinberg equilibrium assumption was tested by chi-square analysis and variants that deviated (PϽ1ϫ10 Ϫ6 ) were removed from the analysis. Variants were excluded from analysis if the MAF was less than 5% in both the AA and non-AAs. The final analysis included 2552 variants from Affymetrix, 165 from SNPlex, and 7 from Sequenom (see Appendix 2, Supplemental Digital Content 2, http://links.lww.com/TP/A323).
Association Testing of Variants Toward Clinical Factors and Trough Concentrations
The importance of clinical factors towards log-transformed dose-normalized troughs over the first 6 months posttransplant was evaluated, with no variants, using a general linear model with time trough obtained posttransplant (1-24) as a categorical variable and a covariance structure to account for correlation between repeated measurements on the same person. Factors explored were recipient race (AA vs. non-AA), age, gender, donor type (living or deceased), diabetes at transplant, and center. We explored time varying covariates such as CCBs, ACE inhibitor and corticosteroid use at time of trough, acute rejection episode Ϯ14 days of the trough, and CrCl nearest the trough. A number of model covariance structures (autoregressive, Toeplitz, and compound symmetry) were considered. The structure which best fit the data, by the Akaike information criterion, in a model with all of the potential covariates listed above, was the Toeplitz covariance structure, which allows the correlation to decline slowly and nonuniformly over time. This structure was used for all models. Factors with F-test P less than 0.15 in backward selection were retained.
Each variant was first tested for association with the log-transformed dose-normalized troughs obtained over the 6 months using a general linear model with time posttransplant (1-24) as a categorical variable and a Toeplitz covariance structure, using an additive genetic model. The analyses were adjusted for center and the clinical factors identified above. For variants where the MAF was more than 5% in non-AA and AAs, all subjects were used to estimate the variant effect. For variants where the MAF in one race was less than 5%, potentially resulting in unreliable estimates, the effect was estimated using the other race where the MAF was more than 5%. Since the subgroup analyses have somewhat less power than the analysis in all subjects, this procedure improves reliability at the cost of underestimating the significance of those variants. Rs776746 was the top variant and all further analyses were adjusted for it. This study aimed to identify novel variants and multiple testing was taken into account by controlling the FDR at 20%, which is common for these types of studies. P values for variant association were ordered in increasing order and denoted by P (1) , …, P (m) . They were considered significant if below a FDR of 20%, that is, P (k) less than 0.2 k/m. We used an effective number of variants mϭ2110, which was computed based on linkage disequilibrium between all variants (70) .
Pharmacogenetic testing is most useful at the beginning of therapy and the effect of variants and clinical factors on the first log-transformed dosenormalized trough (within the first 4 days posttransplant) was evaluated through multiple variant analysis using linear regression models. The significant factors identified initially (center, rs776746 and 39 variants in Table A , Supplemental Digital Content 4, http://links.lww.com/TP/A325) were considered for entry into the final model. Stepwise selection was used with the criterion for entry set at P value less than 0.15 and removal at more than 0.10. The reliability of the final regression models were confirmed by bootstrap resampling (see Appendix 1, Supplemental Digital Content 1, http://links.lww.com/TP/A322).
Troughs and daily doses were compared between AA and non-AAs using nonparametric Wilcoxon-Mann-Whitney. Analyses were conducted using SAS version 9.2 (SAS Institute, Cary, NC).
